Viking Therapeutics (VKTX) Stock Still Looks Overvalued On Its 357% Five Year Run

Viking Therapeutics has ridden a very strong five year share price climb, capped by fresh momentum around its obesity drug pipeline. That raises a straightforward question for investors who care about valuation: Is the current price still anchored to what the biopharma business has built up on its balance sheet, or has it moved far away from its book value?

• Over the past 5 years the stock has gained about 356.8%, which puts a lot of long term optimism on the line when you compare today’s valuation with the company’s underlying equity base.
• The launch of Phase 3 trials for oral VK2735 in obesity can influence expectations for future cash generation and capital needs, which both feed directly into how much weight investors place on Viking Therapeutics’ book value today.
• The analysts covering Viking Therapeutics have run their own numbers. See what analysts think Viking Therapeutics's shares could be worth.

The issue now is whether the recent share price around US$26.72 is meaningfully supported by Viking Therapeutics’ book value when set against the industry average.

If you want to stress test this kind of book value question beyond Viking Therapeutics, run the same filter across 35 high quality undervalued stocks.

Does Viking Therapeutics Look Pricey on Book Value?

P/B fits Viking Therapeutics because the balance sheet is currently more central to the story than revenue or earnings. At around 7.6x P/B, the stock trades at a sizeable premium to the broader biotechs industry, where the average sits near 1.8x. Against closer peers, which cluster around 4.0x, the gap is still wide.

Because the launch of Phase 3 trials for oral VK2735 has sharpened expectations for the obesity franchise, investors are clearly willing to pay a higher multiple for Viking Therapeutics than for typical biotech stocks. The valuation model flags this spread as overvalued relative to the sector and treats the distance as an extreme gap. This signals that current losses and risk are being heavily discounted in the benchmark. That leaves today’s P/B multiple implying a lot of confidence already embedded in the price, and it raises the bar for future clinical and funding outcomes to keep justifying it. Explore the numbers behind Viking Therapeutics's P/B valuation.

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around Viking Therapeutics and turn it into clear, testable stories about what would need to happen next for the share price to look meaningfully higher or lower than today. Each scenario links its number to a specific path for future growth, profitability and risk, giving you something concrete to revisit as fresh trial data, funding decisions and competitive updates are posted on Viking Therapeutics' Community page.

One of the top community narratives on Viking Therapeutics: 79% undervalued

"The large, global demand for obesity treatments is aligning with VK2735’s late-stage development in two formulations..."

Discover why this Narrative puts Viking Therapeutics at 79% undervalued.

Before you act on Viking Therapeutics’ valuation, there is one more signal to check

Balance sheet strength and pipeline hopes only tell part of the story. Recent trading by people inside Viking Therapeutics can add a very different clue about how risks and rewards line up. See the recent insider selling flagged for Viking Therapeutics.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com